Schedule 13G
LGND Schedule 13G filing by Vanguard Capital Management
Vanguard Capital Management reported beneficial ownership of 997.6K shares, representing 12% of LIGAND PHARMACEUTICALS in this filing.
FiledMay 1, 2026
Ownership dateMar 31, 2026
Reported shares997.6K
Reported ownership12%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
149.5K
Shared voting power
997.6K
Sole dispositive power
997.6K
Shared dispositive power
997.6K
Price context
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Close near filing date$227.44as of May 1, 2026
Latest tracked price$302.07as of Aug 5, 2026
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- Vanguard Capital Management
- CIK
- CIK0002100119
- Accession
- 0002100119-26-001292
- Form
- Schedule 13G
Read the filing in context